of 25-70%. The positive prognostic factors reported were not for acute leukemia relapsed after first BMT were performed in homogeneous and their identification was precluded in most Twenty-four patients were male and 14 female, median age
at second BMT was 19 years (range 2-46). Underlying disease was ALL in 17 patients and AML in 21. At the time of second BMT 24 patients were in CR and 14 in relapse, six in the Introduction ALL group and eight in the AML group. Of the 14 patients transplanted in relapse, only three had received reinduction Leukemic relapse is the most frequent cause of treatment failtherapy after relapse. The median time between first and ure after allogeneic bone marrow transplantation (BMT). In second BMT was 13 months (range , with a median time fact, the improvement in survival after BMT over the last decbetween first BMT and relapse of 10 months (range 1-70). ade is largely due to improved supportive care, while the risk Patients characteristics are shown in Table 1 . The median of relapse remained essentially unchanged, [1] [2] [3] varying from 20 follow-up for surviving patients is 47 months (range . to 40% depending on treatment regimen, length of follow-up
The data are analyzed as of 31 July 1996. and patient selection. [4] [5] [6] [7] Patients with more advanced disease, cytogenetic abnormalities and those receiving T cell-depleted marrow have a higher transplant relapse rate ranging between Transplant procedure 50 and 70%. [8] [9] [10] [11] The optimal treatment strategy for patients relapsing after BMT is still an open question. In two large ser-
The donor was a genotypically HLA-identical sibling in all 38 ies, adults with acute leukemia who relapsed after allogeneic patients. In all cases except four, the donor was the same as BMT had a median survival of 3-4 months if no treatment first BMT. The myeloablative regimen used prior to second was administered.
12-13 Some patients, 30-55%, can achieve complete remission (CR) with conventional salvage chemotherapy (CT) but these remissions are generally brief with a 3- Table 1 Patients' characteristics year disease-free survival rate of less than 10%. 14-16 Donor buffy-coat infusion might be an interesting treatment option ALL AML Total in chronic myeloid leukemia (CML) in cytogenetic and hematologic relapse, however, in relapsed AML only brief reported a high (25-50%) 100 day transplant-related mortality Relapse 6 8 14 (TRM) and a probability of leukemia-free survival (LFS) at 4
Median (range) remission 10 (1-33) 11 (5-70) 10 (1-70) years ranging between 11 and 33%, Table 2 ). Two n % P % P % P patients received a polychemotherapeutic protocol for first and second BMT. Graft-versus-host disease (GVHD) prophy-
laxis regimen for both transplants is described in rence. TRM was defined as death occurring in continuous CR after the second BMT: early (before day +100) and late (after a Other variables analyzed with no significant influence result:
day +100).
patient age, sex match at second BMT, conditioning regimen (TBI vs no TBI) at second BMT, GVHD prophylaxis at second BMT. TRM, treatment-related mortality; EFS = event-free survival.
Statistical methods
Event times were measured from the date of second BMT to Results the date of relapse, death or last follow-up. For relapse, patients in CR were censored at the time of death from causes Hematopoietic engraftment other than leukemia or at the time of last follow-up. For TRM, patients were censored at the time of relapse or at time of Four patients were not evaluable for engraftment: one died on last follow-up. For the event-free survival (EFS) analysis, either day −1 of neurotoxicity related to the conditioning regimen relapse or death from other causes were considered events and three died within 21 days of second BMT. All 34 evaluand patients were censored only at the time of last follow-up. able patients demonstrated prompt hematopoietic recovery Variables in Table 3 were studied for their association with with median time to an ANC Ͼ0.5 × 10 9 /l and to PLT TRM, relapse and EFS using χ 2 contingency tables. Prob-Ͼ50 × 10 9 /l of 16 days (range 10-40) and 33 days (range 13-abilities of EFS, relapse and TRM were calculated using the 51) respectively. KM product-limit method. P values Ͻ0.05 were considered as statistically significant.
Survival
The 3-year probability of EFS was 42% (Figure 1) . A diagnosis Table 2 Transplantation procedure of AML was associated with a better EFS (P = 0.027) when compared to a diagnosis of ALL (Figure 2 ). This holds true or in relapse (Figure 1 ). In the group of patients who received two of VOD and two of relapse.
Second BMT in acute leukemia
A Bosi et al 422 regimen in one; moreover, one patient died of interstitial pneumonia from CMV after 54 days. The causes of latetoxicity death were: pulmonary failure from cGVHD in one patient, pulmonary infection (in one patient in association with a Salmonella enteritis sepsis) in two, and fungal meningitis in one. The 3-year probability of TRM was 28%. TRM was similar for patients transplanted in remission or in relapse (Table 3) .
Graft-versus-host disease
Acute GVHD occurred in 13 patients (34.2%) after first BMT and in 19 patients (50%) after second BMT. The incidence of aGVHD after second transplant was 30.7% for patients who experienced aGVHD after the first BMT (4/13), and 60% for those who did not develop aGVHD after first BMT (15/25). There was no significant difference between the ALL and the AML groups in the frequency of acute and chronic GVHD (fatal in one case due to respiratory failure after 56 months).
Of the patients with cGVHD, five have had no evidence of aGVHD after second BMT and none had evidence of cGVHD after first BMT.
Discussion
The management of leukemic relapse after BMT offers various options including induction CT, second BMT and donor leukocyte infusion. The latter is reasonable for patients experiencing chronic phase CML recurrence, while results are discouraging in acute leukemia. 17 In AML patients relapsed after BMT, standard induction CT results in a CR rate of 35% with a median survival time of 8 months; time from BMT to relapse is the most important predictor of response to reinduction CT. 12, 13 In ALL the CR rate for relapsed patients is approximately 50% with a median survival of 14 months; patients with a long interval between BMT and relapse (Ͼ1 year) and those with isolated extramedullary relapse have a better outcome;
12-14 however, most patients eventually relapse and die of uncontrolled leukemia with a 3-year DFS rate less than relapse are high in most reported series. However, this approach is the only one offering a chance of long-term leukemia-free survival. 15, 16 Other major concerns are the high cost of the procedure [33] [34] [35] and the expected lengthening of the Relapse waiting list in BMT Units. Consequently, the identification of certain selection criteria will be required. For these reasons Leukemia recurred in 13 patients (34.2%) after second BMT (seven ALL and six AML). No other statistically significant we performed this review with the aim of clarifying if and in what circumstances it might be justified to offer this treatassociations between relapse and the variables evaluated could be identified. The probability of relapse is 40% at 3 ment option. Observed TRM is of 28.9% (18.4% for early TRM). Patients' years. Relapse was similar for patients transplanted in remission or in relapse.
age, sex match, conditioning regimen and GVHD prophylaxis, remission status at second BMT, incidence of acute GVHD had no impact on TRM. The observed TRM rate is lower than that reported by others. Barrett et al 18 reported a TRM of 47%
Post-BMT complications and causes of death in the European study; in the IBMTR study, TRM rate observed was 40% 19 and the Seattle group reported a TRM of 36%.
20
The incidence of early TRM was 18.4% (seven of 38 patients).
The causes of early death were: aGVHD in two, pulmonary However, all these studies included CML patients who are known to have a high TRM also at the first BMT. 36 On the infection in one, VOD in two, neurotoxicity from conditioning 
